Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.

Daniele Amparore,Sabrina De Cillis,Claude Schulman,Gregor Kadner,Cristian Fiori,Francesco Porpiglia

Minerva urology and nephrology（2023）

引用 0|浏览4

暂无评分

摘要

iTind device provided significant and durable symptom reduction and improved IPSS-QoL for >48 months post treatment. No late postoperative complications were reported beyond 36 months of follow-up. Surgical re-treatment rate for >36 months was 4%.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要